{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-113895","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2026-10-06T11:51:50+00:00","discovered_at":"2026-10-06T11:55:00.264790+00:00","generated_at":"2026-10-12T16:35:56.822669+00:00","sec_items":["1.01","2.02","8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Regeneron, Sanofi expand antibody collaboration; Sanofi to pay $1B upfront, up to $7B in milestones","bullets":["Sixth Amendment to 2009 Antibody LCA covers four new Regeneron antibodies: IL-13, IL-4, IL-4Rα, and IL-4xIL-13 bispecific.","Sanofi to make $1.0B upfront payment; Regeneron eligible for up to $7.0B in development, regulatory, commercial milestones; global profits split 50/50.","Regeneron gets option, per asset after ongoing trials, to add Sanofi's Phase 2/3 lunsekimig (TSLPxIL-13 Nanobody) and another early asset; would reimburse certain dev costs.","Regeneron lead development and pre-approval regulatory party; lead US regulatory/commercialization; Sanofi leads commercialization and ex-US regulatory.","Q3 2026 to include ~$22M pre-tax acquired IPR&D charge, cutting GAAP and non-GAAP EPS by ~$0.18; results not final. Dupixent audit lawsuit dismissed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-113895","json":"https://secwatch.observer/filing/0001104659-26-113895.json","markdown":"https://secwatch.observer/filing/0001104659-26-113895.md","text":"https://secwatch.observer/filing/0001104659-26-113895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/tm2627077d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:35:56.822669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}